Business Context and Reporting Period
Company: BioTime, Inc. (Note: Input metadata referenced Lineage Cell Therapeutics, but the filing text identifies the registrant as BioTime, Inc.)
Reporting Period: Quarterly period ended March 31, 2003.
Status: Development stage company engaged in research and development of synthetic plasma expanders (Hextend, PentaLyte) and organ preservation solutions. The company has incurred cumulative net losses of $34,366,299 since inception.
Key Financial Metrics
| Metric | Q1 2003 | Q1 2002 | Balance Sheet (Mar 31, 2003) |
|---|---|---|---|
| Total Revenue | $96,622 | $57,235 | - |
| Net Loss | $(751,129) | $(706,408) | - |
| Loss Per Share (Basic/Diluted) | $(0.06) | $(0.06) | - |
| Cash and Cash Equivalents | - | - | $723,519 |
| Total Assets | - | - | $1,420,242 |
| Total Liabilities | - | - | $3,187,517 |
| Shareholders' Deficit | - | - | $(1,767,275) |
| Debentures (Net of Discount) | - | - | $2,308,764 |
Operating Expenses: Total expenses were $562,304 for Q1 2003, comprising $224,536 in R&D and $337,768 in General and Administrative (G&A).
Cash Flow: Net cash used in operating activities was $560,913 for the quarter.
Material Changes vs. Prior Period
- Revenue Growth: Royalty revenue increased 68.8% to $96,622 from $57,235 in the prior year quarter, driven by increased sales of Hextend by licensee Abbott Laboratories.
- Expense Reduction: R&D expenses decreased by $36,035 (14%) due to reductions in employee headcount and payroll taxes, partially offset by increased consultant fees.
- Liquidity Decline: Cash and cash equivalents decreased from $1,284,432 at year-end 2002 to $723,519 at March 31, 2003, primarily due to operating losses and an increase in accounts receivable ($510,579).
- Debt Position: The carrying value of debentures increased slightly due to the amortization of debt discount, though the principal obligation remains $3,350,000.
Guidance, Outlook, and Risks
Liquidity Outlook: Management estimates current cash resources, combined with anticipated royalties and license fees, are sufficient to fund operations through March 31, 2004. The company is actively seeking additional capital and new licensing agreements.
Recent Developments:
- CJ Corp. Agreement: In March 2003, BioTime granted an exclusive license for Hextend and PentaLyte in South Korea. A $500,000 initial payment (net of taxes) was received in April 2003 and deferred as revenue.
- Debenture Restructuring: In April 2003, holders of $2.75 million in debentures granted a "pay-in-kind" (PIK) right, allowing the company to pay interest in stock rather than cash for payments due in August 2003 and February 2004. This was done to preserve cash.
Risks and Contingencies:
- Capital Needs: The company requires additional financing to continue clinical trials for PentaLyte and HetaCool. Failure to secure funding could force a curtailment of operations.
- Internal Controls: Management identified a material weakness in accounting and reporting functions due to the performance and supervision of outsourced accounting personnel. Remediation steps are underway.
- Regulatory Approval: Future revenues depend on obtaining FDA and foreign regulatory approvals for PentaLyte and HetaCool, which are not guaranteed.
Investor Verification Checklist
- Cash Runway: Verify if the company has secured the additional equity capital needed to fund clinical trials beyond the projected March 2004 date.
- PIK Interest Impact: Assess the potential dilution to shareholders if the company exercises the "pay-in-kind" right on its debentures.
- Internal Control Remediation: Monitor progress on fixing the material weakness in internal controls regarding outsourced accounting.
- License Revenue Recognition: Confirm the timing of revenue recognition for the CJ Corp. license fee, which is being amortized over eight years rather than recognized immediately.
- Debenture Maturity: Note the $3.35 million principal debt due August 1, 2004, and the company's ability to refinance or repay it.